- Flash Mob for Breast Cancer Empowerment, in partnership with the Tigerlily Foundation, takes place at the Lincoln Memorial in Washington, DC on Saturday 14 October
- International events including support of Susan G. Komen Race for the Cure in Orange County, ‘Boxing Against Breast Cancer’ in Amsterdam and a Dress in Pink Day
- New patient stories, employee profiles and breast cancer facts shared daily throughout October on social media
IRVINE, CA and AMSTERDAM – 27 September 2017 – Agendia, a world leader in personalized medicine and molecular cancer diagnostics, is supporting Breast Cancer Awareness Month with activities throughout late September and October across the United States and Europe around the theme of ‘Breast Cancer – Let’s Make It Personal’.
Agendia has partnered with the Tigerlily Foundation which educates, advocates for, empowers, and supports women in 43 U.S. states before, during and after breast cancer, to organize a Flash Mob for Breast Cancer Empowerment. The Flash Mob will take place outside the Lincoln Memorial in Washington, DC on Saturday 14 October. Breast cancer survivors, supporters, their families and friends will be joined by over 50 dancers from PowerWorx Dance, a local dance studio, to perform a surprise, seemingly impromptu dance routine at 12.00pm, Eastern Time. The flash mob aims to raise awareness of, and show solidarity with, women across the U.S affected by breast cancer.
“Breast cancer can affect women from all walks of life and of all ages. I founded Tigerlily Foundation to unite and support women, especially those under the age of 40, who are going through their own very personal journey. The flash mob will be a powerful, public symbol of strength, hope and joy in the face of the fear and uncertainty that a breast cancer diagnosis universally brings. We are very pleased to be working with Agendia to make this happen,” said Maimah Karmo, Founder and CEO of Tigerlily Foundation and an 11-year survivor of breast cancer.
On Sunday 24 September, 15 employees, family and friends from the Company’s Irvine office formed team ‘MammaSPrint’ to take part in the Susan G. Komen® Race for the Cure in Orange County, California. The team will continue to fundraise throughout October for Susan G. Komen, a non-profit organization that serves millions of women affected by breast cancer in over 60 countries worldwide.
In Amsterdam, Agendia is sponsoring ‘Boxing Against Breast Cancer’ a health, fitness and wellness day for over 60 breast cancer patients which will take place on Thursday 19 October. Organized by the hospital Onze Lieve Vrouwe Gasthuis (OLVG), the event will be hosted at one of the city’s top gyms. The team will also support a patient event in the Netherlands organized by Maastricht University Medical Center on Friday 29 September. In addition, employees across the Company will ‘Dress in Pink’ on Friday 20 October, which is also National Mammography Day in the US.
Dr. William Audeh, Chief Medical Officer at Agendia, said:
“Breast cancer is the most common cancer affecting women, and one in eight will receive a breast cancer diagnosis in their lifetime. During Breast Cancer Awareness Month, our theme of ‘Breast Cancer – Let’s Make It Personal’ recognizes the fact that every woman diagnosed with breast cancer will have a different experience and is an individual, not a statistic. Therefore, the way that each patient’s treatment is managed must be equally personalized, based on a combination of clinical and pathology factors, as well as the unique genomic information from an individual patient’s cancer, provided by MammaPrint®.
“At Agendia, we care deeply about the impact that the MammaPrint test can have in helping to individualize the treatment of women with early-stage breast cancer. We are pleased to be able to play even a small part in the global movement that is Breast Cancer Awareness Month, to help raise awareness and support women everywhere affected by this disease.”
The MammaPrint 70-Gene Breast Cancer Risk-of-Recurrence test analyzes the 70 genes most associated with breast cancer recurrence to provide a High Risk or Low Risk result of a patient’s cancer recurring. It is backed by the highest level of clinical evidence (1A) and is recommended by prestigious international breast cancer treatment guidelines including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the St. Gallen Breast Cancer Consensus.
For more information about MammaPrint visit the new, dedicated section on the Susan G. Komen website.
Follow Agendia’s Twitter, Facebook and LinkedIn pages, and Symphony Sisterhood patient Twitter and Facebook pages for daily patient stories, employee profiles and breast cancer facts throughout October.
– Ends –
MammaPrint is an in vitro diagnostic test, performed in a central laboratory, using the gene expression profile of breast cancer tissue samples to assess a patients’ risk for distant metastasis. MammaPrint is cleared by the US FDA and carries the CE Mark, which certifies that the test complies with the quality standards set by the European In Vitro Diagnostic Directive, enabling the use of the test in the European Union. MammaPrint is indicated for use by physicians as a prognostic marker only, along with other clinical-pathological factors. The test is not intended to determine the outcome of disease, nor to suggest or infer an individual patient’s response to therapy.
Agendia is a privately held, leading molecular diagnostics company that develops and markets genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test, and the BluePrint® Molecular Subtyping Test that provides deeper insight leading to more clinically actionable breast cancer biology.
In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology.
For more information on Agendia or the MammaPrint and BluePrint tests, you can visit Agendia’s patient site at www.KnowYourBreastCancer.com or the corporate site at www.agendia.com.
Follow Agendia, Inc. on Facebook, Twitter, or LinkedIn to keep up-to-date with the latest news.
Ashley Tapp / Lynne Trowbridge / Samantha Cheung
Tel: +44 (0) 20 7866 7855